Reata Pharmaceuticals shares are trading higher after SVB Leerink upgraded the stock from Market Perform to Outperform and raised its price target from $80 to $115.
Portfolio Pulse from Benzinga Newsdesk
Reata Pharmaceuticals' stock has been upgraded from Market Perform to Outperform by SVB Leerink, with a raised price target from $80 to $115.
June 12, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reata Pharmaceuticals (RETA) has been upgraded to Outperform by SVB Leerink, with a price target increase from $80 to $115.
The upgrade from Market Perform to Outperform by SVB Leerink, along with the raised price target from $80 to $115, indicates a positive outlook for Reata Pharmaceuticals. This news is likely to have a positive short-term impact on the stock price, as it reflects increased confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100